**Summary**
Novacyt S.A., an international molecular diagnostics company, released its full-year trading update for 2025, highlighting financial and commercial progress. Key points include
1. **Financial Performance**
Group revenue for FY 2025 is expected at £20.0m, in line with market expectations of £19.8m, representing a 4% growth (5% on a constant currency basis).
Clinical segment sales grew by 3% to £13.8m, driven by a new strategic customer in the APAC region and strong NIPT technology sales (+10%).
Instrumentation segment saw 25% growth to £2.5m, led by the successful launch of the LightBench® Discover instrument.
RUO segment declined by 10% to £3.7m due to reduced Primerdesign product sales.
APAC and Americas regions delivered growth of 10% and 8%, respectively.
Cash position remained strong at £19.2m, with the Group remaining debt-free.
2. **Commercial Highlights**
The LightBench® Discover instrument, launched in July 2025, has been successfully placed in 10 labs, with a robust pipeline for 2026.
The Primerdesign exsig® Mag RapidBead Pro Extraction Kit was launched in November 2025, offering superior DNA/RNA purification performance.
Beta testing for Yourgenes Insight DPYD assay is underway, with a product launch expected in H1 2026.
3. **Outlook**
The Group expects to report full-year results in April 2026.
CEO Lyn Rees emphasized the successful delivery of revenue growth, sequential half-year growth, and a strong foundation for future innovation.
Novacyt remains focused on driving innovation and executing its strategic plans across its Clinical, Instrumentation, and RUO segments.
| Metric | FY 2024 | FY 2025 | Change |
|---|---|---|---|
| Group Statutory Revenue | £19.6m | £20.0m | +2.0% (in line with market expectations) |
| Underlying Group Revenue Growth | N/A | +4% (+5% on constant currency basis) | Excluding Taiwan service lab divestment |
| Clinical Segment Sales | £13.5m | £13.8m | +3% (driven by APAC strategic customer) |
| NIPT Technologies (within Clinical) | N/A | +10% YoY | |
| Instrumentation Segment Sales | £2.0m | £2.5m | +25% (driven by LightBench® Discover) |
| RUO Segment Sales | £4.2m | £3.7m | -10% (reduced Primerdesign catalogue sales) |
| APAC Region Sales | N/A | £5.5m | +10% YoY (Reproductive Health demand) |
| Americas Region Sales | N/A | N/A | +8% YoY |
| H2 Revenue (Sequential Growth) | £9.6m | £10.2m | +6.3% (third consecutive period of growth) |
| EBITDA Losses | N/A | Meets/improves market expectations | Careful cost management |
| Cash Position | N/A | £19.2m (as of 31 Dec 2025) | £23.8m (as of 30 Jun 2025) |
| Debt Status | Debt-free | Debt-free |